APOC3 and fatty liver disease: Vupanorsen, a LICA/GalNac-conjugated PS 2MOE ASO that selectively inhibits ANGPTL3, for the treatment of diabetes, hepatic steatosis, and hypertriglyceridemia (Gaudet et al., 2020), and AKCEA-APOCIII-LRx, a GalNac-conjugated PS 2MOE ASO against APOC-III (Alexander et al., 2019), both delivered SC, are also showing positive results in clinical trials (Table 2).